NUTX Stock Analysis: Buy, Sell, or Hold?
NUTX - Nutex Health Inc. Common Stock
$152.84
2.67 (1.78%)
▲
5d:
+3.92%
30d:
+28.57%
90d:
+60.92%
HOLD
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When NUTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NUTX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: NUTX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$209.08
Based on 5.6% avg growth
INTRINSIC VALUE TODAY
$129.83
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NUTX is currently trading at $152.84, which is considered extended relative to its 30-day fair value range of $123.24 to $144.34. The stock's valuation (Forward PE: 6.6) is in line with its historical norms (7.0). Remarkably, the market is currently pricing in an annual earnings decline of 1.9% over the next few years. This pessimistic expectation contrasts with the company's recent 95.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NUTX is in a uptrend. The price is approaching resistance at $152.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NUTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $235.50 (+56.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NUTX is in a uptrend. The price is approaching resistance at $152.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NUTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $235.50 (+56.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$123.24 -
$144.34
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BEARISH: Price extended above range (+5.9% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 56.8% below Wall St target ($235.50)
Trading Range Analysis
30-Day Trading Range
$123.24 -
$144.34
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$131.15
Resistance Level
$152.50
Current Trend
Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.60
Wall Street Target
$235.50
(+56.8%)
Revenue Growth (YoY)
2.2%
Earnings Growth (YoY)
95.9%
Profit Margin
10.9%
Valuation Discount vs History
-1.9% cheaper
PE vs Historical
6.6 vs 7.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.9%
(market-implied from PE analysis)
1-Year Target
$147.32
(-2%)
2-Year Target
$144.52
(-4%)
3-Year Target
$141.77
(-6%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
$150.36
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 7.2%)
$610.86
(+307%)
Base:
(SPY PE: 6.6, Growth: 7.2%)
$185.11
(+23%)
Bear:
(PE: 5.6, Growth: 7.2%)
$157.35
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (11x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 10.77 | Current EPS (TTM): $13.65
Bull Case
$269.60
(+80%)
Analyst growth 66.7%, PE expands to 11.9
Base Case
$245.09
(+63%)
Market implied 66.7%, PE stable at 10.8
Bear Case
$99.99
(-33%)
Severe decline -20.0%, PE contracts to 9.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.6 to 7.0
Stabilization Target:
$159.27
(+6.1%)
PE Expansion Potential:
+6.1%
Share & Embed Analysis
Last updated: June 23, 2026 11:59 AM ET
Data refreshes hourly during market hours. Next update: 12:59 PM
Data refreshes hourly during market hours. Next update: 12:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUTX showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Frank E Jaumot
BUY
150 shares
2026-03-20
Warren Hosseinion
BUY
252 shares
2026-03-19
Kelvin Spears
BUY
10 shares
2026-03-17
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$244 | 57 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$504 | 60 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$141 | 53 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$22 | 54 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$133 | 58 HOLD |
